Skip to main content
    R

    Rapid Micro Biosystems Inc (RPID)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.74
    +0.09 (+13.67%)

    Market Cap: $32.65M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rapid Micro Biosystems Inc (RPID) Earnings: Report Dates and Results

    Updated Aug 7, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Rapid Micro Biosystems (RPID) is expected to report earnings on Mar 10, 2027. In the quarter ended Jun 30, 2026, Rapid Micro Biosystems reported EPS of -$0.27, below the -$0.26 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    20%(4/20)
    Avg Surprise
    -6.41%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.18 - -$0.14
    5 analysts
    Revenue Consensus
    $13.64M
    Range$12.05M - $15.86M
    6 analysts

    Next Report

    RPID has an expected report date of Mar 10, 2027.

    RPID Earnings Call

    The latest RPID earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 20 quarters below that had an estimate, RPID beat 4, missed 14 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $8.05M, up 10.9% from $7.26M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.27-$0.26-$0.26 - -$0.23-3.85%MissN/A3N/AAug 7, 2026$8.05M
    Mar 31, 2026-$0.31-$0.21-$0.28 - -$0.21-47.62%MissN/A30 up, 0 downMay 13, 2026$8.00M
    Dec 31, 2025-$0.28-$0.23-$0.24 - -$0.22-21.74%MissN/A30 up, 0 downMar 12, 2026$11.28M
    Sep 30, 2025-$0.26-$0.24-$0.27 - -$0.22-8.33%MissN/A40 up, 2 downNov 7, 2025$7.84M
    Jun 30, 2025-$0.27-$0.25-$0.27 - -$0.24-8.00%MissN/A30 up, 0 downAug 12, 2025$7.26M
    Mar 31, 2025-$0.26-$0.27-$0.27 - -$0.27+3.70%BeatN/A10 up, 0 downMay 9, 2025$7.21M
    Dec 31, 2024-$0.22-$0.21-$0.24 - -$0.21-4.76%MissN/A21 up, 1 downFeb 28, 2025$8.22M
    Sep 30, 2024-$0.26-$0.25-$0.26 - -$0.25-4.00%MissN/A20 up, 0 downNov 1, 2024$7.60M
    Jun 30, 2024-$0.29-$0.28-$0.28 - -$0.27-3.57%MissN/A30 up, 0 downAug 2, 2024$6.62M
    Mar 31, 2024-$0.31-$0.29-$0.30 - -$0.28-6.90%MissN/A30 up, 0 downMay 3, 2024$5.61M
    Dec 31, 2023-$0.26-$0.30-$0.31 - -$0.29+13.33%BeatN/A30 up, 0 downMar 1, 2024$6.34M
    Sep 30, 2023-$0.31-$0.28-$0.32 - -$0.28-10.71%MissN/A30 up, 0 downNov 3, 2023$6.14M
    Jun 30, 2023-$0.33-$0.33N/A0.00%In lineN/A30 up, 0 downAug 4, 2023$5.00M
    Mar 31, 2023-$0.32-$0.36-$0.39 - -$0.34+11.11%BeatN/A40 up, 0 downMay 5, 2023$5.04M
    Dec 31, 2022-$0.39-$0.36-$0.39 - -$0.33-8.33%MissN/A30 up, 0 downMar 3, 2023$4.37M
    Sep 30, 2022-$0.38-$0.36-$0.38 - -$0.36-5.56%MissN/A30 up, 0 downNov 10, 2022$4.74M
    Jun 30, 2022-$0.31-$0.35N/A+11.43%BeatN/AN/A0 up, 0 downAug 12, 2022$3.86M
    Mar 31, 2022-$0.35-$0.32-$0.38 - -$0.27-9.38%MissN/A40 up, 0 downMay 10, 2022$4.16M
    Dec 31, 2021-$0.35-$0.28-$0.34 - -$0.19-25.00%MissN/A4N/AMar 4, 2022$5.21M
    Sep 30, 2021-$0.39-$0.39-$0.43 - -$0.370.00%In lineN/A31 up, 0 downNov 11, 2021$6.90M
    Jun 30, 2021-$20.01-$0.40N/AN/AN/AN/AN/AN/AJul 16, 2021$6.13M
    Mar 31, 2021-$0.69N/AN/AN/AN/AN/AN/AN/AJun 2, 2021$5.00M
    Last 22 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.07, after -$1.08 the year before. It was -$21.44 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.07N/A
    Dec 31, 2024-$1.08N/A
    Dec 31, 2023-$1.22N/A
    Dec 31, 2022-$1.43N/A
    Dec 31, 2021-$21.44N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 6,300 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20266,2958
    2026Q1Mar 31, 20264,7538
    2025Q4Dec 31, 20255,2788
    2025Q3Sep 30, 20253,9878
    2025Q2Jun 30, 20254,2638
    2025Q1Mar 31, 20253,5756
    2024Q4Dec 31, 20244,3077
    2024Q3Sep 30, 20243,5226

    2026Q2 Earnings Call

    Opening remarks

    Michael Beaulieu Investor Relations Good morning, and thank you for joining the Rapid Micro Biosystems Second Quarter Earnings Call. Joining me on the call are Rob Spignesi, President and Chief Executive Officer; and Sean Wirtjes, Chief Financial Officer. This morning, we issued a press release announcing our second quarter results. A copy of the release is available on the company's website at rapidmicrobio.com under Investors in the News and Events section. Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements, including, but not limited to, statements relating to Rapid Micro's financial condition, assumptions regarding future financial performance, anticipated future cash usage, statements relating to the company's term loan facility, guidance for 2026, including revenue, expenses, gross margin, system placements and validation activities, expectations for and planned activities related to Rapid Micro's business development and growth, including the expected benefits from our distribution and collaboration agreement with MilliporeSigma, customer interest and adoption of the Growth Direct System and the impact of the Growth Direct system on their businesses and operations and statements regarding the potential impact of general macroeconomic conditions on our business and that of our customers. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors, including our ability to meet publicly announced guidance, the impact of our existing and any future indebtedness on our ability to operate our business, our ability to achieve the milestones necessary to access any future tranches under our existing debt facility and to comply with all of its obligations thereunder, our ability to access additional capital, such as through the exercise of our recently issued warrants, our ability to deliver products to customers and recognize revenue and market and macroeconomic conditions. For a more detailed list and description of the risks and uncertainties associated with Rapid Micro's business, please refer to the Risk Factors section of our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as updated from time to time in subsequent filings with the SEC. We urge you to consider these factors, and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. Please note that today's remarks include certain non-GAAP financial measures.

    Frequently Asked Questions About RPID

    When is Rapid Micro Biosystems's next earnings date?

    Rapid Micro Biosystems's next earnings report is expected for Mar 10, 2027.

    Did RPID beat earnings estimates last quarter?

    No. Rapid Micro Biosystems reported EPS of -$0.27 for the quarter ended Jun 30, 2026, below the -$0.26 estimate by 3.85%.

    What EPS do analysts expect from RPID next quarter?

    The consensus EPS estimate for Rapid Micro Biosystems for the quarter ending Dec 31, 2026 is -$0.16 from 5 analysts, with estimates from -$0.18 to -$0.14.

    How often does RPID beat earnings estimates?

    Rapid Micro Biosystems beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -11.82%.